Located in Yanqi Industrial Development Zone, Huairou District, Beijing, the company is the first localized R&D and manufacturing base established by GoeGoe Honglin Pharmaceutical Co. in China. With a registered capital of USD 15.8 million, it is a wholly U.S.-owned, certified National High-Tech Enterprise. The company is equipped with internationally advanced pharmaceutical manufacturing equipment and intelligent quality control systems, and receives technical support from a U.S.-based expert management team.

Located in Zhenjiang Economic and Technological Development Zone, Jiangsu Province, the company serves as another strategic expansion by GoeGoe Honglin Pharmaceutical Co. following Beijing Honglin Pharmaceutical Co., Ltd. With a registered capital of USD 30 million and a site covering approximately 80,000 square meters, the facility is equipped with multiple automated production lines and imported core process equipment, integrated with advanced information systems and environmental control systems, thereby comprehensively ensuring both product quality and production efficiency. The first phase of the Jiangsu base has been successfully completed and is now operational. It has an annual production capacity of 1.2 billion tablets and 600 million capsules, which demonstrates highly efficient and stable commercial manufacturing capabilities.